{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:36:32Z","timestamp":1793406992387,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,13]],"date-time":"2015-01-13T00:00:00Z","timestamp":1421107200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40268-014-0078-0","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T04:36:21Z","timestamp":1421037381000},"page":"45-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Martino","family":"Belvederi Murri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argentina","family":"Guaglianone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Respino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Innamorati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pompili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,13]]},"reference":[{"key":"78_CR1","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.4088\/JCP.10m06438","volume":"72","author":"RJ Gurrera","year":"2011","unstructured":"Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72:1222\u20138.","journal-title":"J Clin Psychiatry."},{"key":"78_CR2","first-page":"18","volume":"50","author":"A Shalev","year":"1989","unstructured":"Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50:18\u201325.","journal-title":"J Clin Psychiatry."},{"key":"78_CR3","doi-asserted-by":"crossref","unstructured":"Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol. 2005;28:197\u2013204.","DOI":"10.1097\/01.wnf.0000172079.80795.5f"},{"key":"78_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","volume":"16","author":"D Tarsy","year":"2002","unstructured":"Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16:23\u201345.","journal-title":"CNS Drugs."},{"key":"78_CR5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00005053-198608000-00010","volume":"174","author":"HG Pope Jr","year":"1986","unstructured":"Pope HG Jr, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis. 1986;174:493\u20135.","journal-title":"J Nerv Ment Dis."},{"key":"78_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200923060-00003","volume":"23","author":"JN Trollor","year":"2009","unstructured":"Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23:477\u201392.","journal-title":"CNS Drugs."},{"key":"78_CR7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00004850-200411000-00007","volume":"19","author":"N Chakraborty","year":"2004","unstructured":"Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. 2004;19:351\u20133.","journal-title":"Int Clin Psychopharmacol."},{"key":"78_CR8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1176\/jnp.2007.19.4.488","volume":"19","author":"E Abay","year":"2007","unstructured":"Abay E, Kose R. Amisulpride-induced neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci. 2007;19:488\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"78_CR9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd2806","volume":"8","author":"G Grunder","year":"2009","unstructured":"Grunder G, Hippius H, Carlsson A. The \u2018atypicality\u2019 of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009;8:197\u2013202.","journal-title":"Nat Rev Drug Discov."},{"key":"78_CR10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","volume":"20","author":"J Horacek","year":"2006","unstructured":"Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389\u2013409.","journal-title":"CNS Drugs."},{"key":"78_CR11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.111.105189","volume":"201","author":"JN Trollor","year":"2012","unstructured":"Trollor JN, Chen X, Chitty K, et al. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry. 2012;201:52\u20136.","journal-title":"Br J Psychiatry."},{"key":"78_CR12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2009.01425.x","volume":"121","author":"H Verdoux","year":"2010","unstructured":"Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand. 2010;121:4\u201310.","journal-title":"Acta Psychiatr Scand."},{"key":"78_CR13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.comppsych.2006.10.004","volume":"48","author":"RJ Gurrera","year":"2007","unstructured":"Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry. 2007;48:205\u201311.","journal-title":"Compr Psychiatry."},{"key":"78_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/026988110101500405","volume":"15","author":"PN Biswasl","year":"2001","unstructured":"Biswasl PN, Wilton LV, Pearcel GL, et al. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol. 2001;15:265\u201371.","journal-title":"J Psychopharmacol."},{"key":"78_CR15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/pds.1937","volume":"19","author":"B Margeti\u0107","year":"2010","unstructured":"Margeti\u0107 B, Aukst-Margeti\u0107 B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf. 2010;19:429\u201335.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"78_CR16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/157488609787354387","volume":"4","author":"Y Odagaki","year":"2009","unstructured":"Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf. 2009;4:84\u201393.","journal-title":"Curr Drug Saf."},{"key":"78_CR17","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0278-5846(95)00269-3","volume":"19","author":"M Amore","year":"1995","unstructured":"Amore M, Zazzeri N. Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:1323\u201334.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"78_CR18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/nedt.2006.2.2.235","volume":"2","author":"A Yacoub","year":"2006","unstructured":"Yacoub A, Francis A. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr Dis Treat. 2006;2:235\u201340.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"78_CR19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2190\/PM.39.4.h","volume":"39","author":"Y Chen","year":"2009","unstructured":"Chen Y, Guo JJ, Steinbuch M, et al. Risk of neuroleptic malignant syndrome in patients with bipolar disorder: a retrospective, population-based case\u2013control study. Int J Psychiatry Med. 2009;39:439\u201350.","journal-title":"Int J Psychiatry Med."},{"key":"78_CR20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4088\/JCP.10m06791","volume":"73","author":"M Nakamura","year":"2012","unstructured":"Nakamura M, Yasunaga H, Miyata H, et al. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry. 2012;73:427\u201330.","journal-title":"J Clin Psychiatry."},{"key":"78_CR21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/070674371205700810","volume":"57","author":"RE Nielsen","year":"2012","unstructured":"Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome: an 11-year longitudinal case\u2013control study. Can J Psychiatry. 2012;57:512\u20138.","journal-title":"Can J Psychiatry."},{"key":"78_CR22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/acps.12222","volume":"130","author":"YP Su","year":"2014","unstructured":"Su YP, Chang CK, Hayes RD, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. 2014;130:52\u201360.","journal-title":"Acta Psychiatr Scand."},{"key":"78_CR23","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn, text revision. Washington, DC: American Psychiatric Association; 2000."},{"key":"78_CR24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","volume":"142","author":"JL Levenson","year":"1985","unstructured":"Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142:1137\u201345.","journal-title":"Am J Psychiatry."},{"key":"78_CR25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.psychres.2005.05.003","volume":"135","author":"PS Sachdev","year":"2005","unstructured":"Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res. 2005;135:249\u201356.","journal-title":"Psychiatry Res."},{"key":"78_CR26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1176\/ajp.143.10.1227","volume":"143","author":"HG Pope Jr","year":"1986","unstructured":"Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986;143:1227\u201333.","journal-title":"Am J Psychiatry."},{"key":"78_CR27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7125(16)30278-4","volume":"77","author":"SN Caroff","year":"1993","unstructured":"Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185\u2013202.","journal-title":"Med Clin North Am."},{"key":"78_CR28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hup.376","volume":"17","author":"D Berardi","year":"2002","unstructured":"Berardi D, Dell\u2019Atti M, Amore M, et al. Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol. 2002;17:99\u2013102.","journal-title":"Hum Psychopharmacol."},{"key":"78_CR29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0006-3223(97)00530-1","volume":"44","author":"D Berardi","year":"1998","unstructured":"Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case\u2013control study. Biol Psychiatry. 1998;44:748\u201354.","journal-title":"Biol Psychiatry."},{"key":"78_CR30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1600-0447.1986.tb02694.x","volume":"73","author":"A Shalev","year":"1986","unstructured":"Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986;73:337\u201347.","journal-title":"Acta Psychiatr Scand."},{"key":"78_CR31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/14737175.7.4.423","volume":"7","author":"SN Caroff","year":"2007","unstructured":"Caroff SN, Campbell EC, Sullivan KA. Neuroleptic malignant syndrome in elderly patients. Expert Rev Neurother. 2007;7:423\u201331.","journal-title":"Expert Rev Neurother."},{"key":"78_CR32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1049909110369532","volume":"27","author":"N Licup","year":"2010","unstructured":"Licup N. Olanzapine for nausea and vomiting. Am J Hosp Palliat Care. 2010;27:432\u20134.","journal-title":"Am J Hosp Palliat Care."},{"key":"78_CR33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/hup.250","volume":"16","author":"MS Arnaout","year":"2001","unstructured":"Arnaout MS, Antun FP, Ashkar K. Neuroleptic malignant syndrome with olanzapine associated with severe hypernatremia. Hum Psychopharmacol. 2001;16:279\u201381.","journal-title":"Hum Psychopharmacol"},{"key":"78_CR34","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1345\/aph.18151","volume":"32","author":"GA Filice","year":"1998","unstructured":"Filice GA, McDougall BC, Ercan-Fang N, et al. Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacother. 1998;32:1158\u20139.","journal-title":"Ann Pharmacother."},{"key":"78_CR35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/00004714-200012000-00021","volume":"20","author":"D Sierra-Biddle","year":"2000","unstructured":"Sierra-Biddle D, Herran A, Diez-Aja S, et al. Neuropletic malignant syndrome and olanzapine. J Clin Psychopharmacol. 2000;20:704\u20135.","journal-title":"J Clin Psychopharmacol."},{"key":"78_CR36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0736-4679(00)00263-8","volume":"19","author":"SC Stanfield","year":"2000","unstructured":"Stanfield SC, Privette T. Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. J Emerg Med. 2000;19:355\u20137.","journal-title":"J Emerg Med."},{"key":"78_CR37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3109\/00048679809073880","volume":"32","author":"V Johnson","year":"1998","unstructured":"Johnson V, Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Aust NZ J Psychiatry. 1998;32:884\u20136.","journal-title":"Aust NZ J Psychiatry."},{"key":"78_CR38","doi-asserted-by":"crossref","unstructured":"Verma R, Junewar V, Rathaur BP. An atypical case of neuroleptic malignant syndrome precipitated by valproate. BMJ Case Rep. 2014;2014. doi: 10.1136\/bcr-2013-202578 .","DOI":"10.1136\/bcr-2013-202578"},{"key":"78_CR39","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4103\/0019-5359.37787","volume":"61","author":"B Mishra","year":"2007","unstructured":"Mishra B, Mishra B, Sahoo S, et al. Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine. Indian J Med Sci. 2007;61:570\u20133.","journal-title":"Indian J Med Sci."},{"key":"78_CR40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1600-0447.2005.00578.x","volume":"112","author":"J Nielsen","year":"2005","unstructured":"Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand. 2005;112:238\u201340.","journal-title":"Acta Psychiatr Scand."},{"key":"78_CR41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2146\/ajhp090091","volume":"67","author":"TC Randolph","year":"2010","unstructured":"Randolph TC. Possible contribution of XYY syndrome to neuroleptic malignant syndrome in a child receiving quetiapine. Am J Health Syst Pharm. 2010;67:459\u201361.","journal-title":"Am J Health Syst Pharm."},{"key":"78_CR42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/14740338.2.1.21","volume":"2","author":"DK Farver","year":"2003","unstructured":"Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf. 2003;2:21\u201335.","journal-title":"Expert Opin Drug Saf."},{"key":"78_CR43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0b013e31821160c4","volume":"33","author":"GV Bakken","year":"2011","unstructured":"Bakken GV, Rudberg I, Molden E, et al. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit. 2011;33:222\u20136.","journal-title":"Ther Drug Monit."},{"key":"78_CR44","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00455-010-9307-z","volume":"26","author":"JJ Sico","year":"2011","unstructured":"Sico JJ, Patwa H. Risperidone-induced bulbar palsy-like syndrome. Dysphagia. 2011;26:340\u20133.","journal-title":"Dysphagia."},{"key":"78_CR45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/JCP.0b013e3181ad2064","volume":"29","author":"L Ghio","year":"2009","unstructured":"Ghio L, Fornaro G, Rossi P. Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report. J Clin Psychopharmacol. 2009;29:391\u20132.","journal-title":"J Clin Psychopharmacol."},{"key":"78_CR46","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/01.jcp.0000145346.61041.18","volume":"24","author":"SG Sugden","year":"2004","unstructured":"Sugden SG, Bourgeois JA, Kile SJ, et al. Neuroleptic malignant syndrome with dermatologic complications. J Clin Psychopharmacol. 2004;24:676\u20138.","journal-title":"J Clin Psychopharmacol."},{"key":"78_CR47","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.v65n0403","volume":"65","author":"J Ananth","year":"2004","unstructured":"Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464\u201370.","journal-title":"J Clin Psychiatry."},{"key":"78_CR48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003088-199324020-00005","volume":"24","author":"MW Jann","year":"1993","unstructured":"Jann MW, Grimsley SR, Gray EC, et al. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet. 1993;24:161\u201376.","journal-title":"Clin Pharmacokinet."},{"key":"78_CR49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000119344","volume":"35","author":"M Amore","year":"1997","unstructured":"Amore M, Zazzeri N, Berardi D. Atypical neuroleptic malignant syndrome associated with clozapine treatment. Neuropsychobiology. 1997;35:197\u20139.","journal-title":"Neuropsychobiology."},{"key":"78_CR50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF03324659","volume":"18","author":"G Gambassi","year":"2006","unstructured":"Gambassi G, Capurso S, Tarsitani P, et al. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging Clin Exp Res. 2006;18:266\u201370.","journal-title":"Aging Clin Exp Res."},{"key":"78_CR51","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1016\/0893-133X(95)00203-P","volume":"14","author":"J Gerlach","year":"1996","unstructured":"Gerlach J, Lublin H, Peacock L. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology. 1996;14:35S\u20139S.","journal-title":"Neuropsychopharmacology."},{"key":"78_CR52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00004714-199510000-00010","volume":"15","author":"P Sachdev","year":"1995","unstructured":"Sachdev P, Kruk J, Kneebone M, et al. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol. 1995;15:365\u201371.","journal-title":"J Clin Psychopharmacol."},{"key":"78_CR53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1345\/aph.18286","volume":"33","author":"JL Karagianis","year":"1999","unstructured":"Karagianis JL, Phillips LC, Hogan KP, et al. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother. 1999;33:623\u201330.","journal-title":"Ann Pharmacother."},{"issue":"Suppl 3","key":"78_CR54","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0924-977X(00)80467-8","volume":"10","author":"T Gallarda","year":"2000","unstructured":"Gallarda T, Olie JP. Neuroleptic malignant syndrome in an 72-year-old-man with Alzheimer\u2019s disease: a case report and review of the literature. Eur Neuropsychopharmacol. 2000;10(Suppl 3):357.","journal-title":"Eur Neuropsychopharmacol."},{"key":"78_CR55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.genhosppsych.2008.03.007","volume":"30","author":"P Angelopoulos","year":"2008","unstructured":"Angelopoulos P, Markopoulou M, Kyamidis K, et al. Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride. Gen Hosp Psychiatry. 2008;30:482\u20134.","journal-title":"Gen Hosp Psychiatry."},{"key":"78_CR56","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1258\/rsmmsl.49.4.298","volume":"49","author":"H Ball","year":"2009","unstructured":"Ball H, de Waal H, Craig K. An unrecognised case of withdrawal neuroleptic malignant syndrome: a case report. Med Sci Law. 2009;49:298\u2013300.","journal-title":"Med Sci Law."},{"key":"78_CR57","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.4088\/JCP.v65n1219f","volume":"65","author":"EC Atbasoglu","year":"2004","unstructured":"Atbasoglu EC, Ozguven HD, Can SM, et al. Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome. J Clin Psychiatry. 2004;65:1724\u20135.","journal-title":"J Clin Psychiatry."},{"key":"78_CR58","first-page":"536","volume":"34","author":"MC Tu","year":"2011","unstructured":"Tu MC, Hsiao CC. Amisulpride and neuroleptic malignant syndrome. Chang Gung Med J. 2011;34:536\u201340.","journal-title":"Chang Gung Med J."},{"key":"78_CR59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/WNF.0b013e3180cfe3a0","volume":"30","author":"V Peritogiannis","year":"2007","unstructured":"Peritogiannis V, Tsouli S, Pappas D, et al. Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. Clin Neuropharmacol. 2007;30:245\u20136.","journal-title":"Clin Neuropharmacol."},{"key":"78_CR60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","volume":"280","author":"G Perrault","year":"1997","unstructured":"Perrault G, Depoortere R, Morel E, et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280:73\u201382.","journal-title":"J Pharmacol Exp Ther."},{"key":"78_CR61","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.schres.2008.07.005","volume":"105","author":"S Natesan","year":"2008","unstructured":"Natesan S, Reckless GE, Barlow KB, et al. Amisulpride the \u2018atypical\u2019 atypical antipsychotic: comparison to haloperidol, risperidone and clozapine. Schizophr Res. 2008;105:224\u201335.","journal-title":"Schizophr Res."},{"key":"78_CR62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","volume":"51","author":"J Leon de","year":"2010","unstructured":"de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80\u20138.","journal-title":"Psychosomatics."},{"key":"78_CR63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/jnp.2007.19.4.477","volume":"19","author":"HS Duggal","year":"2007","unstructured":"Duggal HS. Possible neuroleptic malignant syndrome associated with paliperidone. J Neuropsychiatry Clin Neurosci. 2007;19:477\u20138.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"78_CR64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JCP.0b013e3181c9c7ef","volume":"30","author":"C Mantas","year":"2010","unstructured":"Mantas C, Kalabokis G, Goulia P, et al. Possible neuroleptic malignant syndrome during paliperidone administration: a case report. J Clin Psychopharmacol. 2010;30:89\u201391.","journal-title":"J Clin Psychopharmacol."},{"key":"78_CR65","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.pnpbp.2010.12.006","volume":"35","author":"C Han","year":"2011","unstructured":"Han C, Lee SJ, Pae CU. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:650\u20131.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"78_CR66","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1176\/appi.neuropsych.23.1.E14","volume":"23","author":"RB Nayak","year":"2011","unstructured":"Nayak RB, Bhogale GS, Patil NM, et al. Paliperidone-induced neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci. 2011;23:E14\u20135.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"78_CR67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1345\/aph.1G470","volume":"40","author":"MC Borovicka","year":"2006","unstructured":"Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother. 2006;40:139\u201342.","journal-title":"Ann Pharmacother."},{"key":"78_CR68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hup.578","volume":"19","author":"NS Gray","year":"2004","unstructured":"Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson\u2019s disease: a diagnostic challenge. Hum Psychopharmacol. 2004;19:205\u20137.","journal-title":"Hum Psychopharmacol."},{"key":"78_CR69","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0149-2918(04)90182-8","volume":"26","author":"J Leibold","year":"2004","unstructured":"Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther. 2004;26:1105\u20138.","journal-title":"Clin Ther."},{"key":"78_CR70","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.pra.0000361282.95962.9f","volume":"15","author":"AL Lewis","year":"2009","unstructured":"Lewis AL, Pelic C, Kahn DA. Malignant catatonia in a patient with bipolar disorder, B12 deficiency, and neuroleptic malignant syndrome: one cause or three? J Psychiatr Pract. 2009;15:415\u201322.","journal-title":"J Psychiatr Pract."},{"key":"78_CR71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/15622970600774202","volume":"8","author":"ME Ozen","year":"2007","unstructured":"Ozen ME, Yumru M, Savas HA, et al. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry. 2007;8:42\u20134.","journal-title":"World J Biol Psychiatry."},{"key":"78_CR72","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00004714-200212000-00015","volume":"22","author":"RG Murty","year":"2002","unstructured":"Murty RG, Mistry SG, Chacko RC. Neuroleptic malignant syndrome with ziprasidone. J Clin Psychopharmacol. 2002;22:624\u20136.","journal-title":"J Clin Psychopharmacol."},{"issue":"Suppl 19","key":"78_CR73","first-page":"6","volume":"64","author":"SM Stahl","year":"2003","unstructured":"Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(Suppl 19):6\u201312.","journal-title":"J Clin Psychiatry."},{"key":"78_CR74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/17425250802670482","volume":"5","author":"B Green","year":"2009","unstructured":"Green B. Zotepine: a clinical review. Expert Opin Drug Metab Toxicol. 2009;5:181\u20136.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"78_CR75","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/JCP.0b013e31822c2a04","volume":"31","author":"WC Hsu","year":"2011","unstructured":"Hsu WC, Lin ST, Chen CC, et al. A self-limiting case of atypical neuroleptic malignant syndrome associated with zotepine. J Clin Psychopharmacol. 2011;31:667\u20139.","journal-title":"J Clin Psychopharmacol."},{"key":"78_CR76","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1592\/phco.2005.25.8.1156","volume":"25","author":"JH Tsai","year":"2005","unstructured":"Tsai JH, Yang P, Yen JY, et al. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy. 2005;25:1156\u20139.","journal-title":"Pharmacotherapy."},{"key":"78_CR77","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S1010-7940(03)00332-4","volume":"24","author":"S Mieno","year":"2003","unstructured":"Mieno S, Asada K, Horimoto H, et al. Neuroleptic malignant syndrome following cardiac surgery: successful treatment with dantrolene. Eur J Cardiothorac Surg. 2003;24:458\u201360.","journal-title":"Eur J Cardiothorac Surg."},{"key":"78_CR78","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00228-007-0355-8","volume":"63","author":"D Kato","year":"2007","unstructured":"Kato D, Kawanishi C, Kishida I, et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol. 2007;63:991\u20136.","journal-title":"Eur J Clin Pharmacol."},{"key":"78_CR79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S1461145799001388","volume":"2","author":"TM Adityanjee","year":"1999","unstructured":"Adityanjee TM, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol. 1999;2:129\u201344.","journal-title":"Int J Neuropsychopharmacol."},{"key":"78_CR80","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/2045125312438215","volume":"2","author":"CK Chang","year":"2012","unstructured":"Chang CK, Harrison S, Lee W, et al. Ascertaining instances of neuroleptic malignant syndrome in a secondary mental healthcare electronic medical records database: the SLAM BRC Case Register. Ther Adv Psychopharmacol. 2012;2:75\u201383.","journal-title":"Ther Adv Psychopharmacol."},{"key":"78_CR81","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002826-198808000-00006","volume":"11","author":"JH Friedman","year":"1988","unstructured":"Friedman JH, Davis R, Wagner RL. Neuroleptic malignant syndrome. The results of a 6-month prospective study of incidence in a state psychiatric hospital. Clin Neuropharmacol. 1988;11:373\u20137.","journal-title":"Clin Neuropharmacol."},{"key":"78_CR82","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00005053-199403000-00007","volume":"182","author":"VR Velamoor","year":"1994","unstructured":"Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994;182:168\u201373.","journal-title":"J Nerv Ment Dis."},{"key":"78_CR83","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00004583-199211000-00028","volume":"31","author":"MM Woodbury","year":"1992","unstructured":"Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992;31:1161\u20134.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"78_CR84","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","volume":"164","author":"JR Strawn","year":"2007","unstructured":"Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870\u20136.","journal-title":"Am J Psychiatry."},{"key":"78_CR85","doi-asserted-by":"crossref","unstructured":"Gurrera RJ, Velamoor V, Cernovsky ZZ. A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol. (Epub 22 Aug 2013).","DOI":"10.1097\/JCP.0b013e31829ab413"},{"key":"78_CR86","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.","edition":"5"},{"key":"78_CR87","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.genhosppsych.2011.03.003","volume":"33","author":"S Ochi","year":"2011","unstructured":"Ochi S, Kawasoe K, Abe M, et al. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. Gen Hosp Psychiatry. 2011;33:640\u20132.","journal-title":"Gen Hosp Psychiatry."},{"key":"78_CR88","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4088\/JCP.v65n0520d","volume":"65","author":"J Ananth","year":"2004","unstructured":"Ananth J, Johnson KM, Levander EM, et al. Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate. J Clin Psychiatry. 2004;65:724.","journal-title":"J Clin Psychiatry."},{"key":"78_CR89","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/ajp.156.2.169","volume":"156","author":"RJ Gurrera","year":"1999","unstructured":"Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999;156:169\u201380.","journal-title":"Am J Psychiatry."},{"key":"78_CR90","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1248\/bpb.b13-00310","volume":"36","author":"Y Ohno","year":"2013","unstructured":"Ohno Y, Shimizu S, Tokudome K. Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull. 2013;36:1396\u2013400.","journal-title":"Biol Pharm Bull."},{"key":"78_CR91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1744-6163.2010.00292.x","volume":"47","author":"D Steele","year":"2011","unstructured":"Steele D, Keltner NL, McGuiness TM. Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome? Perspect Psychiatr Care. 2011;47:58\u201362.","journal-title":"Perspect Psychiatr Care."},{"key":"78_CR92","first-page":"155","volume":"24","author":"PJ Perry","year":"2012","unstructured":"Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012;24:155\u201362.","journal-title":"Ann Clin Psychiatry."},{"key":"78_CR93","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1345\/aph.1P787","volume":"45","author":"AA Sokoro","year":"2011","unstructured":"Sokoro AA, Zivot J, Ariano RE. Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool. Ann Pharmacother. 2011;45:e50.","journal-title":"Ann Pharmacother."},{"key":"78_CR94","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/JCP.0b013e3181ef09f8","volume":"30","author":"AA Monte","year":"2010","unstructured":"Monte AA, Waksman JC. Chronic olanzapine, serotonin receptors, and subsequent serotonin toxicity. J Clin Psychopharmacol. 2010;30:628\u20139.","journal-title":"J Clin Psychopharmacol."},{"key":"78_CR95","first-page":"U2058","volume":"119","author":"K Marlowe","year":"2006","unstructured":"Marlowe K, Schirgel D. Quetiapine and citalopram: aetiological significances in serotonin syndrome. NZ Med J. 2006;119:U2058.","journal-title":"NZ Med J."},{"key":"78_CR96","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s004060050043","volume":"248","author":"HJ Assion","year":"1998","unstructured":"Assion HJ, Heinemann F, Laux G. Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci. 1998;248:231\u20139.","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"78_CR97","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.genhosppsych.2012.11.004","volume":"35","author":"F Uguz","year":"2013","unstructured":"Uguz F, Sonmez EO. Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report. Gen Hosp Psychiatry. 2013;35:327.","journal-title":"Gen Hosp Psychiatry."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-014-0078-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0078-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0078-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:09:06Z","timestamp":1747404546000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-014-0078-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,13]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1007\/s40268-014-0078-0","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,13]]}}}